CHMP recommends approval of Dupixent in the EU for the treatment of patients with COPD

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a favorable opinion for the approval of Dupixent (dupilumab) as maintenance treatment in adults with uncontrolled COPD with elevated blood eosinophilia .

This recommendation is based on data from the BOREAS and NOTUS phase 3 trials. Studies show that Dupixent significantly reduces exacerbations and improves respiratory function compared to placebo.

If validated, Dupixent would become the first targeted therapy for COPD in Europe in over a decade. The European Commission is expected to make a final decision in the coming months.